Status:
TERMINATED
Development and Evaluation of a ChlorHexidine Gluconate bAthing pRotocol for Healthcare Settings in Low- and Middle-income Countries
Lead Sponsor:
University of Pennsylvania
Collaborating Sponsors:
Children's Hospital of Philadelphia
University of Botswana
Conditions:
Multidrug Resistant Bacterial Infection
Eligibility:
All Genders
1-6 years
Phase:
NA
Brief Summary
The overall goal of the ChlorHexidine gluconate (CHG) bAthing pRotocol for healthcare settings in low- and Middle-income countries (CHARM) study is to explore the safety, efficacy and feasibility of u...
Detailed Description
Neonatal sepsis is the third most common cause of neonatal deaths and multidrug-resistant Gram-negative bacteria are now the leading cause of sepsis among hospitalized neonates in south Asia and sub-S...
Eligibility Criteria
Inclusion
- Neonates 1-6 days old admitted to the neo-natal unit expected to stay at least 7 days
Exclusion
- Patients with a current weight of \<1kg
- Patients with a current corrected gestational age of \<28 weeks (by Ballard score, or by dates if Ballard is not done)
- Patients with a current diagnosis of hypothermia
- Patients with a current diagnosis of skin rash or skin injury
Key Trial Info
Start Date :
February 19 2025
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 19 2025
Estimated Enrollment :
19 Patients enrolled
Trial Details
Trial ID
NCT06590675
Start Date
February 19 2025
End Date
March 19 2025
Last Update
July 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Princess Marina Hospital
Gaborone, Botswana